Oculis Raises $144 Million to Advance Life-Changing Eye Treatments Worldwide

Oculis (Nasdaq: OCS), a pioneering global biopharmaceutical company dedicated to revolutionizing eye care, has successfully raised an impressive $144 million in its latest funding round. This significant capital infusion is poised to accelerate the company’s mission of saving sight and addressing critical eye diseases with high unmet medical needs. Oculis boasts a robust clinical-stage pipeline featuring innovative product candidates, including OCS-01 eye drops, currently in Phase 3 development targeting diabetic macular edema (DME) and managing inflammation and pain after ocular surgery. Additionally, OCS-02 eye drops are making strides in Phase 2 trials for dry eye disease and uveitis, while OCS-05 represents a groundbreaking approach to treating acute optic neuritis and other neuro-ophthalmic disorders. This funding will enable Oculis to enhance its research capabilities, advance ongoing clinical trials, and broaden its product portfolio to meet the demands of patients worldwide. The company’s strategic operations across Switzerland, the US, Europe, and China reflect its commitment to delivering life-changing treatments globally. Led by a seasoned management team with a proven track record in the pharmaceutical industry, supported by esteemed international healthcare investors, Oculis is on a path to redefine eye care and make significant impacts on patient outcomes. As the company continues its journey toward innovation in ophthalmology, this funding milestone marks a pivotal step toward achieving its vision of comprehensive solutions for various eye diseases.